

Published in final edited form as:

Chem Commun (Camb). 2011 July 28; 47(28): 7962–7964. doi:10.1039/c1cc12570b.

Drug release from hydrazone-containing peptide amphiphiles

John B. Matson^a and Samuel I. Stupp^{*,a,b,c,d}

^aInstitute for BioNanotechnology in Medicine, Northwestern University, Chicago, IL, 60611, USA

^bDepartment of Chemistry, Northwestern University, Evanston, IL 60208, USA

^cDepartment of Materials Science and Engineering, Northwestern University, Evanston, IL, 60208, USA

^dFeinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA

Abstract

Hydrolytically-labile hydrazones in peptide amphiphiles were studied as degradable tethers for drug release from nanofiber gels. On-resin addition of the novel compound tri-Bochydrazido adipic acid to a lysine ϵ -amine allowed for precise placement of a hydrazide in a peptide sequence. Hydrazone formation and hydrolysis were examined by addition and release of nabumetone from a peptide amphiphile matrix.

Delivery of drugs through implantable materials and devices has transformed several areas of medicine, including diabetes treatment, contraception, and cardiovascular repair.^{1, 2} However, increased control over drug release rates and greater biocompatibility and biodegradability of the delivery materials are still necessary improvements. Especially promising new varieties of implantable biomaterials are those made from biodegradable, self-assembling small molecules.^{3, 4} Not only are such systems more biocompatible compared with traditional polymeric gels, but all components of these systems can also be completely characterized on a molecular scale. Despite their promise as materials, sustained drug delivery from biodegradable, small molecule gels is still an underexplored area in the fields of drug delivery and regenerative medicine.^{5, 6}

Over the past decade, our laboratory has developed and studied peptide amphiphiles (PAs) programmed to self-assemble into high aspect ratio nanofibers.⁷ These PAs are a broad class of molecules that have recently received great attention due to their promise as bioactive materials in regenerative applications ranging from central nervous system regeneration and angiogenesis to bone, cartilage, and enamel regeneration, as well as cancer therapeutics.⁸⁻¹⁵ PAs are synthesized by attaching a hydrophobic tail to a short peptide sequence that includes charged residues to promote solubility and control gelation through electrolyte screening. When the peptide sequence design includes a strong β -sheet forming sequence, PAs can self-assemble into long, filamentous aggregates in aqueous solution.⁷ These nanostructures are approximately 10 nm in width and up to several microns in length and can be thought of as supramolecular polymers. Charge screening by addition of salts, especially multivalent counterions, or a change in pH induces network formation and gelation at concentrations on the order of 1% by weight.¹⁶ Previous studies on PA systems have shown the capabilities of PAs to support, signal and deliver cells through the efficient

© The Royal Society of Chemistry [year]

*Fax: (+312) 503-2482; Tel: (+312) 503-6713; s-stupp@northwestern.edu..

†Electronic Supplementary Information (ESI) available: Full experimental details and characterization data on new compounds, SAXS fittings and aggregate parameters. See DOI: 10.1039/b000000x/

display of a bioactive peptide sequence.^{9, 17} Here we explore a new method for the delivery of soluble small molecules from PA gels through the use of hydrolytically labile hydrazone tethers. These small molecules may take the form of therapeutic drugs or biological signals.

Control of drug release rate can often be accomplished by covalently attaching a drug to a hydrolytically labile bond, such as a hydrazone, acetal or orthoester.¹⁸ Typically, the release rate is governed by the pH of the surrounding media, with faster release observed in acidic (pH 5-6) environments compared with physiological media (pH 7.4). Hydrazone bonds are convenient hydrolytically labile bonds due to the usually facile incorporation of hydrazides into delivery materials.¹⁹ However, site-specific incorporation of hydrazides into peptides via solid phase peptide synthesis is still synthetically challenging.

We first attempted on-resin addition of protected hydrazides by the previously reported strategy of adding Boc-NHNHC(O)CH₂CH₂COOH onto a lysine ε-amine.^{20, 21} However, we found couplings with this reagent to be very inefficient due to undesired intramolecular cyclization reactions, which others have also noted (see Supporting Information for details).^{22, 23} A second attempted strategy was to use (Boc)₂NN(Boc)CH₂COOH to reveal peptide hydrazines after cleavage, as reported by Melnyk.²⁴ Though the synthesis was effective, the resulting peptide hydrazines were found to undergo oxidative decomposition under the reaction conditions required for hydrazone formation. Inspired by Melnyk's synthesis, we synthesized triply-protected hydrazido acid **4** for use in SPPS. It was expected that the carbonyl of the hydrazide would provide more oxidative stability compared with the hydrazine.

Synthesis of **4** was accomplished in three steps from previously reported adipic acid monobenzyl ester (**1**) according to Scheme 1. First, *tert*-butylcarbazate was coupled to **1** using EDC and DPTS, affording monoprotected hydrazide **2** (EDC = *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride and DPTS = dimethylaminopyridinium *p*-toluene sulfonate²⁵). Addition of Boc₂O to **2** yielded the triprotected derivative, **3**. Hydrogenolysis of the benzyl ester with Pd/C furnished triprotected hydrazido acid **4**. All reactions showed good to excellent yields, and no chromatography was required (see Supporting Information for full synthetic details and characterization).

Applying building block **4** to the synthesis of potentially bioactive materials, hydrazide-containing PA **5** was produced using standard Fmoc-based solid-phase peptide synthesis conditions. A free amine was generated on-resin by addition of a Lys(Mtt) residue (Mtt = 4-methyltrityl) with selective removal of the Mtt protecting group using 5% TFA in CH₂Cl₂. Hydrazino acid **4** was activated using HBTU and DIEA and added on-resin to the exposed lysine ε-amine (HBTU = 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and DIEA = *N,N*-diisopropylethylamine). Following cleavage using 95% TFA, PA **5** was purified by HPLC. The unprotected hydrazide was found to be oxidatively stable in air in organic solvents at 40 °C for at least 24 h.

The ketone-containing, non-steroidal anti-inflammatory drug nabumetone (4-(6-methoxy-2-naphthyl)-2-butanone) (**Nb**) was chosen as the model drug to serve as a release probe. Condensation of **Nb** with PA **5** was carried out in DMSO at room temperature overnight to form hydrazone-containing PA **6**, which was purified by HPLC (Scheme 2). Structural characterization of PAs **5** and **6** was then carried out to assess the self-assembly of these novel PAs.

PAs **5** and **6** were characterized in aqueous solution by conventional transmission electron microscopy (TEM) and small angle X-ray scattering (SAXS) (Figure 1). TEM of PA **5** showed long, cylindrical nanofibers typical of many PAs synthesized in our laboratory.²⁶

Some bundling of fibers can be observed in the TEM image. TEM of PA **6** showed similar cylindrical nanofibers, though they appeared shorter and less bundled than those of PA **5**. SAXS in aqueous solution was used to further investigate the aggregates formed from PAs **5** and **6**. A slope of -1 in the low q region is indicative of cylindrical aggregates and would be expected;²⁷ however, the slight deviation from the -1 slope observed in the SAXS curve of PA **6** (Figure 1D) is likely a result of a small contribution of bundled aggregates. The even steeper slope in the low q region seen in the PA **5** scattering curve (Figure 1C) is consistent with the higher-order aggregates (bundles) seen in the TEM. We attribute the bundling observed in PA **5** to interfiber hydrogen bonding between surface hydrazide groups. Addition of **Nb** yields a hydrazone that is less capable of hydrogen bonding, which may explain the reduced number of higher-order aggregates observed in PA **6**. Excluding the low q region, the SAXS curves can be reasonably fitted to a polydisperse core-shell cylinder form factor (Supporting Information). The best fit parameters yielded an average fiber diameter of 7.1 nm for PA **5** and 7.0 nm for PA **6**, supporting TEM results that addition of **Nb** did not alter fiber dimensions.

To investigate the release of **Nb** from PA **6**, a mixture of PA **6** with diluent PA C₁₆V₂A₂E₂ (1:1 w/w, structure shown in Supporting Information) was prepared and gelled with CaCl₂. Scanning electron microscopy (SEM) of the gel (Figure 2A) shows the expected fibrous morphology. The release kinetics of **Nb** were measured into a sink solution of buffer by monitoring absorbance at 330 nm (Figure 2B). As we are interested in using drug-delivering PA materials as injectable gels for the long-term, sustained delivery of drugs, signals, and cells, we chose to investigate release kinetics at physiological pH. Although hydrazones are often designated as exhibiting high hydrolytic stability at physiological pH, slow hydrolysis is often still observed.²⁸ Release was observed over 24 d, with an initial burst release but eventual conversion to a zero-order release profile. We speculate that the burst release may be due to some free **Nb** in the gel that occurs as a result of sample preparation.

In summary, a small molecule building block (**4**) for incorporation of hydrazides into peptides has been synthesized. Under standard coupling conditions, **4** can be added on-resin to a lysine ϵ -amine, revealing a free hydrazide upon cleavage from the resin. We demonstrated an application of this chemistry by developing a hydrazide-containing PA, to which a small molecule drug could be tethered via hydrazone formation. Drug tethering was found not to alter the assembly of the PA into filamentous aggregates. The small molecule drug could then be slowly released from the gel into aqueous solution. Further studies on small molecule drug release from PA gels are currently underway in our laboratory. We expect that building block **4** will be useful in several areas of peptide and polymer-based medicine, including peptide-based biomaterials, peptide labeling and polymeric drug conjugation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the NIDCR, grant No. 2R01DE015920-06 and the NIBIB, grant No. 2R01EB003806-06A2. JBM was supported by a Baxter Early Career Development Award in Bioengineering. We are grateful to the Institute for BioNanotechnology in Medicine (IBNAM) Chemistry Core, the Biological Imaging Facility (BIF), the Integrated Molecular Structure Education and Research Center (IMSERC) and the Electron Probe Instrumentation Center (EPIC) of the Northwestern University Atomic- and Nanoscale Characterization Experimental Center (NUANCE) for instrument use. NUANCE Center is supported by NSF-NSEC, NSFMRSEC, Keck Foundation, the State of Illinois, and Northwestern University. We acknowledge Dr. Steven Weigand and the DuPont-Northwestern-Dow Collaborative Access Team (DND-CAT) Synchrotron Research Center at the Advanced Photon Source (APS) at Argonne National Lab for assistance with SAXS measurements. Use of the APS

was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357. Matt Webber and Dr. Ronit Bitton of the authors' laboratory are acknowledged for help with SEM and SAXS, respectively.

Notes and references

1. Goldberg M, Langer R, Jia XQ. *J. Biomater. Sci.-Polym. Ed.* 2007; 18:241–268. [PubMed: 17471764]
2. LaVan DA, McGuire T, Langer R. *Nat. Biotechnol.* 2003; 21:1184–1191. [PubMed: 14520404]
3. Dankers PYW, Meijer EW. *Bull. Chem. Soc. Jpn.* 2007; 80:2047–2073.
4. Cui HG, Webber MJ, Stupp SI. *Biopolymers.* 2010; 94:1–18. [PubMed: 20091874]
5. Kapadia MR, Chow LW, Tsihlis ND, Ahanchi SS, Hrabie JA, Murar J, Martinez J, Popowich DA, Jiang Q, Saavedra JE, Keefer LK, Hulvat JF, Stupp SI, Kibbe MP. *J. Vasc. Surg.* 2008; 47:173–182. [PubMed: 18178471]
6. Branco MC, Pochan DJ, Wagner NJ, Schneider JP. *Biomaterials.* 2010; 31:9527–9534. [PubMed: 20952055]
7. Hartgerink JD, Beniash E, Stupp SI. *Science.* 2001; 294:1684–1688. [PubMed: 11721046]
8. Webber MJ, Kessler JA, Stupp SI. *J. Intern. Med.* 2010; 267:71–88. [PubMed: 20059645]
9. Silva GA, Czeisler C, Niece KL, Beniash E, Harrington DA, Kessler JA, Stupp SI. *Science.* 2004; 303:1352–1355. [PubMed: 14739465]
10. Rajangam K, Behanna HA, Hui MJ, Han XQ, Hulvat JF, Lomasney JW, Stupp SI. *Nano Lett.* 2006; 6:2086–2090. [PubMed: 16968030]
11. Webber MJ, Han XQ, Murthy SNP, Rajangam K, Stupp SI, Lomasney JW. *J. Tissue Eng. Regen. M.* 2010; 4:600–610. [PubMed: 20222010]
12. Mata A, Geng YB, Henrikson KJ, Aparicio C, Stock SR, Satcher RL, Stupp SI. *Biomaterials.* 2010; 31:6004–6012. [PubMed: 20472286]
13. Shah RN, Shah NA, Lim MMD, Hsieh C, Nuber G, Stupp SI. *Proc. Natl. Acad. Sci. U. S. A.* 2010; 107:3293–3298. [PubMed: 20133666]
14. Huang Z, Newcomb CJ, Bringas P Jr. Stupp SI, Snead ML. *Biomaterials.* 2010; 31:9202–9211. [PubMed: 20869764]
15. Standley SM, Toft DJ, Cheng H, Soukasene S, Chen J, Raja SM, Band V, Band H, Cryns VL, Stupp SI. *Cancer Res.* 2010; 70:3020–3026. [PubMed: 20354185]
16. Stendahl JC, Rao MS, Guler MO, Stupp SI. *Adv. Funct. Mater.* 2006; 16:499–508.
17. Webber MJ, Tongers J, Renault MA, Roncalli JG, Losordo DW, Stupp SI. *Acta Biomater.* 2010; 6:3–11. [PubMed: 19635599]
18. Ihre HR, De Jesus OLP, Szoka FC, Frechet JMJ. *Bioconjugate Chem.* 2002; 13:443–452.
19. Gauthier MA, Klok HA. *Chem. Commun.* 2008:2591–2611.
20. Shao J, Tam JP. *J. Am. Chem. Soc.* 1995; 117:3893–3899.
21. Dirksen A, Dirksen S, Hackeng TM, Dawson PE. *J. Am. Chem. Soc.* 2006; 128:15602–15603. [PubMed: 17147365]
22. Guy L, Vidal J, Collet A, Amour A, Reboud-Ravaux M. *J. Med. Chem.* 1998; 41:4833–4843. [PubMed: 9822552]
23. Grandjean C, Gras-Masse H, Melnyk O. *Chem. Eur. J.* 2001; 7:230–239. [PubMed: 11205015]
24. Bonnet D, Grandjean C, Rousselot-Pailley P, Joly P, Bourel-Bonnet L, Santraine V, Gras-Masse H, Melnyk O. *J. Org. Chem.* 2003; 68:7033–7040. [PubMed: 12946145]
25. Moore JS, Stupp SI. *Macromolecules.* 1990; 23:65–70.
26. Palmer LC, Stupp SI. *Acc. Chem. Res.* 2008; 41:1674–1684. [PubMed: 18754628]
27. Glatter, O.; Kratky, O. *Small Angle X-ray Scattering.* Academic Press Inc.; New York: 1982.
28. Kalia J, Raines RT. *Angew. Chem., Int. Ed.* 2008; 47:7523–7526.




Figure 1.
TEM and SAXS of PA 5 (A and C) and PA 6 (B and D).






Figure 2. SEM (A) and release profile (B) of **Nb** from gel of PA **6** mixed 1:1 with diluent PA into buffer at physiological pH (n=5).

**Scheme 1.**

Synthesis of triply-protected hydrazide building block for solid phase peptide synthesis.

Reagents and conditions: i) *tert*-butylcarbazate, EDC, DPTS, CH₂Cl₂, 2 h, 83%; ii) Boc₂O, DMAP, NEt₃, CH₂Cl₂, 2 h, 94%; iii) H₂ (1 atm), Pd/C, EtOH, 4 h, 86%.



Scheme 2.
Synthesis of drug-tethered PA by hydrazone formation.